Poseida Therapeutics, Inc.: share-based compensation expense

What this measure means

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2019-01-01 to 2023-12-31. The SEC response was captured on 2026-09-21.

This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.

Selected filing history

Related financial histories

• Poseida Therapeutics, Inc.: total assets
• Poseida Therapeutics, Inc.: total liabilities
• Poseida Therapeutics, Inc.: stockholders equity
• Poseida Therapeutics, Inc.: cash and cash equivalents
• Poseida Therapeutics, Inc.: net income or loss
• Poseida Therapeutics, Inc.: operating cash flow
• Poseida Therapeutics, Inc.: capital expenditure payments
• Poseida Therapeutics, Inc.: revenue
• Poseida Therapeutics, Inc.: financing cash flow
• Poseida Therapeutics, Inc.: investing cash flow
• Poseida Therapeutics, Inc.: retained earnings or deficit
• Poseida Therapeutics, Inc.: basic weighted-average shares
• Poseida Therapeutics, Inc.: diluted weighted-average shares
• Poseida Therapeutics, Inc.: basic earnings per share
• Poseida Therapeutics, Inc.: diluted earnings per share
• Poseida Therapeutics, Inc.: income tax expense or benefit
• Poseida Therapeutics, Inc.: net property, plant and equipment
• Poseida Therapeutics, Inc.: operating income or loss
• Poseida Therapeutics, Inc.: current assets
• Poseida Therapeutics, Inc.: interest expense
• Poseida Therapeutics, Inc.: current liabilities
• Poseida Therapeutics, Inc.: current accounts payable
• Poseida Therapeutics, Inc.: operating expenses
• Poseida Therapeutics, Inc.: research and development expense

Inspect the source

Entity

Poseida Therapeutics, Inc. / CIK 0001661460

Captured

2026-09-21T17:22:21.198Z

SEC response SHA-256

8e8061f544ee288f78c4db2836ca8be8533a1ccc8a7f695fb2859689f21321f9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001661460.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))